All In MedTech

Device Trial Radar · NCT07214272

A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing

A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing Procedures Using the Next Generation Fraxel® FTX Laser System in Participants With Dyschromia, Cutaneous Lesions, and Periorbital Rhytids

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

49

Actual

Start

Oct 17, 2025

Primary completion

Aug 24, 2026

Study completion Dec 2, 2026

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 9, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a prospective, post-marketing (Phase 4) non-registrational single-arm, open-label, multicenter study.

Conditions

  • Skin Resurfacing

Interventions

  • Fraxel® FTX Laser SystemDevice

    The Fraxel Laser System has two fiber-laser sources that are contained in a single Console. The Console is electrically connected to the facility power source. Laser energy produced by the unit is delivered to the tissue through the Handpiece, which is connected to the Console by the Handpiece Cable. Treatments are delivered through removable, disposable Treatment Tips which attach to the Handpiece. A Treatment Key is required to activate treatments and is inserted into the port on the side of the Touchscreen. The system includes two lasers with wavelengths of 1550 nm and 1927 nm. The two-wavelength option allows for targeted treatment of different tissue depths, and the wavelength can be selected through the Console Touchscreen. Interchangeable Tips allow for treatment of both small and large areas.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EndpointTime frame: 26 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Dermatology Cosmetic Laser Associates of La Jolla, Inc. d/b/a West Dermatology Research Center

    La Jolla, California

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.